Aveanna Beats on Q3 EPS and Revenue, Raises 2026 Targets — Stock Falls Anyway

Aveanna Healthcare posted $0.23 in adjusted earnings per share for the third quarter on Thursday, beating the $0.21 consensus by two cents and improving from $0.15 a year earlier. Revenue reached $695.54 million against analyst expectations of $679.48 million, an 11.8 percent increase year over year. By Friday's close, the stock had fallen 4.7 percent, shedding $0.57 to $11.66.

The market's verdict deserves scrutiny. A beat on both lines, raised guidance, and a 25 percent jump in adjusted EBITDA to $100.1 million ordinarily do not produce a sell-off. What the numbers did not say explains the gap.

What did the quarter actually deliver?

Growth was broad-based. All three segments reported higher revenue. Home Health and Hospice grew 15.6 percent, supported by 19.6 percent more admissions and 24 percent more episodes. Management raised its long-term organic growth outlook for Private Duty Services to 5–6 percent and for Home Health and Hospice to 8–10 percent, while reaffirming 8–10 percent for Medical Solutions.

Management raised 2026 guidance to revenue above $2.695 billion and adjusted EBITDA above $374 million. The balance sheet shows real cash generation: year-to-date operating cash flow of $157.5 million and free cash flow of $141.2 million. Liquidity totaled $492 million, and the company said substantially all variable-rate debt is hedged through December 2029. Aveanna plans to pursue acquisitions while targeting leverage below 3x in 2027 — a promise, it should be noted, that depends on deal discipline the company has yet to demonstrate in this cycle.

Return on equity stood at 80.70 percent with a net margin of 10.56 percent. The return figure flatters: the debt-to-equity ratio of 4.47 shows how leveraged the equity base is. High leverage cuts both ways, and investors tracking the company's Medicaid exposure have flagged it as a persistent concern.

Takeaway: the quarter was genuinely strong; the leverage beneath it is the caveat.

Why did the stock fall despite the beat?

California sits at the center of the story. The state's planned $60 million PDN rate investment is currently viewed by California as a supplemental payment covering only the first half of 2027, while Aveanna is advocating for it to become permanent. The company said it will not make meaningful base-wage increases for California nurses until it has more certainty about ongoing reimbursement.

That freeze cuts both ways. It restrains costs now, but reimbursement uncertainty and caregiver staffing pressures could weigh on growth later. A supplemental payment with a six-month horizon is not a rate increase; it is a trial, and Aveanna's wage policy now hinges on Sacramento's decisions.

Management also flagged a choppier fourth quarter. It expects seasonal softness around the holidays and noted that Q4 2025 contained an extra week, making year-over-year comparisons tougher. It offered a mid-$90 million range as a prudent Q4 adjusted EBITDA planning anchor. In plain words: do not extrapolate the third quarter's momentum into the fourth.

Who is selling, and how much?

Insider activity is the loudest signal in the filing. In transactions dated Thursday, August 20, major shareholder J.H. Whitney Equity Partners V sold 12,496,077 shares at an average price of $11.50, totaling $143,704,885.50. On the same day, major shareholder Paul Vigano sold 14,500,002 shares, also at $11.50, for $166,750,023.00.

Over the last 90 days, insiders have sold 48,566,081 shares valued at $558,509,932. Insiders currently own 5.30 percent of the stock. Sponsor exits after an IPO are routine; the scale and the identical $11.50 price still merit attention.

What do the analysts say?

The sell side moved up after the results:

• Truist Financial raised its target from $11.00 to $15.00 with a "hold" rating (August 24)
• BMO Capital Markets lifted its target from $10.00 to $14.00 with an "outperform" rating (August 14)
• Royal Bank of Canada restated an "outperform" rating (Friday)
• Raymond James restated a "strong-buy" rating (Thursday)
• Weiss Ratings upgraded from "hold (c+)" to "buy (b-)" (October 14)

According to MarketBeat, the consensus rating is "Moderate Buy" with an average price target of $14.25, drawn from one Strong Buy, six Buy, and four Hold ratings.

The technical picture shows the tension. The stock trades above its 200-day moving average of $9.44 but below its 50-day average of $13.06. The 12-month range runs from $5.93 to $14.71. Friday's volume of 1,015,173 shares came in at roughly half the average of 2,039,156. The company carries a market cap of $2.55 billion, a PE ratio of 9.46, a PEG ratio of 0.80, and a beta of 2.03 — a valuation that assumes the growth holds and the debt behaves.

Aveanna identified hospice as a priority for mergers and acquisitions, a potential growth avenue, though acquisitions require capital that leverage targets may constrain.

The quarter beat, the guidance rose, and the insiders sold — each fact is true at once.